Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

GM1 gangliosidosis type 1


Other Names for this Disease
  • Beta galactosidase deficiency type 1
  • Gangliosidosis generalized GM1 infantile form
  • Gangliosidosis generalized GM1 type 1
  • GLB deficiency type 1
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Conferences



ORDR-Sponsored Conferences

  • Lysosomal Disease Network's 10th Annual WORLD Symposium 2014, Monday, February 10, 2014 - Friday, February 14, 2014
    Location: Manchester Grand Hyatt San Diego, San Diego, CA
    Description: This symposium is designed for basic, translational and clinical researchers, patient advocacy groups, clinicians, and all others who are interested in learning more about the latest discoveries in the management and treatment of lysosomal diseases, and the clinical investigation of these advances. This meeting will help researchers and clinicians to better manage and understand diagnostic options for patients with lysosomal diseases; to identify areas requiring additional basic and clinical research, public policy and regulatory attention; and to identify and explore the latest findings in the natural history of lysosomal diseases.

  • 2013 Lysosomal Disease Gordon Research Conference and Gordon Research Seminar, Saturday, April 13, 2013 - Friday, April 19, 2013
    Location: Lucca (Barga), Italy
    Description: Conference goals: To support participation by junior investigators, including graduate students, postdoctoral fellows and new investigators who do not yet have individual and/or independent sources of funding to support their participation in such conferences. The goal is to have at least 40% of the participants at this meeting in this category and NIH funding will help ensure this level of participation. Indeed, at the 2011 inaugural meetings, fully one-third of the participants were graduate students/postdoctoral fellows/junior faculty. The selection of the meeting as host to a GRS will further enhance such participation by the next generation of leaders in the lysosomal disease research community. To further stimulate applications by investigators-in-training, a number of short talks will be chosen prior to the meeting based on abstract submissions, and moreover, a poster session, comprising nine short talks, will be chosen at the meeting on the basis of the posters which generate the most interest during the afternoon poster sessions.

  • RDCRN 3rd Conference on Clinical Research for Rare Diseases, Tuesday, October 02, 2012
    Location: Hilton Washington DC/Rockville Hotel & Executive Meeting Center, Rockville, MD
    Description: Clinical research in rare diseases presents a number of challenges and unique issues that are not usually considered in the training of clinical investigators through existing training programs. Goals of the conference include: direct instruction of trainees and new investigators in rare disease research methodology; development of a reusable curriculum/syllabus on rare disease research methodology; and stimulation of ideas regarding the unique issues facing investigators engaged in the study of rare diseases.

  • 2011 Lysosomal Disease Gordon Research Conference, Sunday, January 23, 2011 - Friday, January 28, 2011
    Location: Hotel Galvez, Galveston, TX
    Description: This Gordon Research Conference had sessions on topics ranging from the basic science of lysosomal biology and function (but with strong emphasis on pathogenic mechanisms of lysosomal disease), relationships of lysosomal diseases to other neurological diseases, pathogenic cascades, biomarkers, recent advances in therapy, and clinical trials and design. In addition, there was a hot topics session (with speakers chosen close to the time of the meeting so as to include the most recent developments) and a poster session (nine short talks chosen at the meeting on the basis of the posters that generated the most interest during the afternoon poster sessions). In addition, a number of short talks were chosen prior to the meeting based on abstract submissions.

  • VI International Conference on Rare Diseases and Orphan Drugs (ICORD 2010): Global Approach to Accessibility in Rare Diseases, Orphan Drugs and Neglected Diseases , Thursday, March 18, 2010 - Saturday, March 20, 2010
    Location: Palais Rouge Convention Center, Palermo, Buenos Aires, Argentina
    Description: For the first time, the VI International Conference on Rare Diseases and Orphan Drugs (ICORD 2010) was convened in the southern hemisphere in agreement with its aim of globalization of rare diseases research and orphan products development activities.

  • WORLD Symposium 2010 (Lysosomal Disease Network's 6th Annual Research Meeting), Wednesday, February 10, 2010 - Friday, February 12, 2010
    Location: Miami Hilton Downtown, Miami, Florida
    Description: The specific aims of this meeting were to (1) emphasize the strategies for, and identify the obstacles to, moving from translational research to clinical trials; (2) coalesce members of the LD network into functional research collaborations and present to the LDN community progress on the specific projects that are part of the funded U54 RDCRN grant; (3) foster interdisciplinary collaboration with the overall goal of improving knowledge of basic discoveries and clinical manifestations of these diseases; (4) provide an educational forum for young investigators, clinicians, and researchers in the field; (5) identify and discuss the latest findings in the natural history of lysosomal diseases, diagnostic testing and screening, and treatment, with specific focus on (a) inflammatory components of lysosomal diseases and autophagy, especially in the central nervous system, (b) new treatments of the central nervous systems, and (c) ethics and efficacy in treating the presymptomatic or asymptomatic patient; and (6) identify areas requiring additional basic and clinical research and public policy and regulatory attention, such as ethics and economics, and factors that impact implementation of therapy, including newborn screening.